Amylyx Pharmaceuticals
AMLX
136 hedge funds and large institutions have $262M invested in Amylyx Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 50 increasing their positions, 31 reducing their positions, and 16 closing their positions.
100% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 16
61% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 31
39% more capital invested
Capital invested by funds: $188M → $262M (+$73.3M)
11% more funds holding
Funds holding: 122 → 136 (+14)
10.73% more ownership
Funds ownership: 72.67% → 83.41% (+11%)
14% less call options, than puts
Call options by funds: $524K | Put options by funds: $606K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$20.3M |
| 2 |
Millennium Management
New York
|
+$8.85M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.45M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$5.73M |
| 5 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$5.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$5.81M |
| 2 |
Jane Street
New York
|
-$1.55M |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$1.39M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.32M |
| 5 |
Walleye Capital
New York
|
-$953K |
AMLX Hedge Fund Activity: Q1 2025 in Review
136 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q1 2025, worth a combined $262M — up 39% from $188M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new AMLX positions and 16 closed out — a net gain of 16 holders — while 50 added to existing stakes and 31 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $20.3M. The largest seller was Bank of America, cutting an estimated $5.81M.
- 136 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q1 2025, up from 122 in Q4 2024.
- Funds reported $262M of Amylyx Pharmaceuticals stock for Q1 2025, up 39% quarter-over-quarter.
- 32 funds opened new Amylyx Pharmaceuticals positions in Q1 2025 and 16 closed out, a net change of +16 holders.
- The largest Amylyx Pharmaceuticals buyer in Q1 2025 was Adage Capital Partners, an estimated $20.3M added.
- The largest Amylyx Pharmaceuticals seller in Q1 2025 was Bank of America, an estimated $5.81M sold.
Based on aggregated 13F filings for Q1 2025.